Drugs / GB3010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06054984 | Sep 2021 → Jun 2024 | malignant pancreatic neoplasm | Ruijin Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB3010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06054984 ↗ |
| Modality | Cell therapy | “The TCRT cells used in this clinical trial were derived from the patient's autologous peripheral-blood T cells and were genetically transduced” NCT06054984 ↗ |
| Route | Intravenous | “by intravenous injection” NCT06054984 ↗ |
| Target | TP53 | “a T-cell Receptor that recognizes the RAS/TP53” NCT06054984 ↗ |